Welcome to our dedicated page for Fibrobiologics news (Ticker: FBLG), a resource for investors and traders seeking the latest updates and insights on Fibrobiologics stock.
FibroBiologics (FBLG) is a Houston-based clinical-stage biotechnology company pioneering fibroblast cell therapies for chronic diseases like cancer, multiple sclerosis, and wound healing. This page serves as the definitive source for verified news, press releases, and clinical updates directly from FibroBiologics and trusted partners.
Investors and researchers will find timely updates on clinical trial progress, patent developments, and strategic collaborations with organizations like Charles River. Content spans FDA submissions, manufacturing advancements, and scientific breakthroughs in regenerative medicine.
All materials are curated for accuracy and relevance, providing stakeholders with actionable insights into FBLG’s pipeline and market position. Bookmark this page or check back regularly to stay informed about fibroblast therapy innovations shaping modern medicine.
FibroBiologics (Nasdaq: FBLG) has been granted a patent by the European Patent Office for a novel cancer treatment method using modified fibroblasts to deliver anti-cancer agents. The patent (Number 19795975.2) covers methods and compositions for enhancing fibroblasts' ability to target cancerous tissues and deliver tumor-inhibiting agents directly to cancer cells.
This innovative approach aims to improve the effectiveness of cancer treatments by leveraging fibroblasts' natural ability to penetrate tumor tissues and modulate immune responses. The technology could potentially address challenges faced by traditional therapies, such as tumor penetration, and may offer new possibilities for treating primary, metastatic, and treatment-resistant tumors.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation in the 2024 Maxim Healthcare Virtual Summit. CEO Pete O'Heeron will engage in a fireside chat on October 16, 2024, at 10:00 a.m. ET.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
Based in Houston, FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, interested parties can visit the company's website or contact them directly via email.
FibroBiologics (Nasdaq: FBLG) announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2024 Cell & Gene Meeting on the Mesa Conference in Phoenix, Arizona, on October 7, 2024. The presentation will focus on updates regarding the company's pre-clinical IND-enabling studies in chronic wound healing and psoriasis, as they prepare for a phase I/II diabetic foot ulcer (DFU) clinical trial with their CYWC628 topically administered fibroblast spheroid product candidate.
Dr. Khoja emphasized the company's approach of leveraging the regenerative potential of fibroblasts for tissue repair and immune modulation. FibroBiologics aims to create innovative cell-based approaches for treating chronic diseases. The presentation is scheduled for 5:45 p.m. MST in the FLW Ballroom F.
FibroBiologics (Nasdaq: FBLG) has engaged Southern Star Research as its CRO in Australia to prepare for a Phase 1/2 clinical trial of CYWC628, a treatment for diabetic foot ulcers. This partnership aims to leverage Australia's high-quality clinical trial infrastructure and R&D incentives. CYWC628 is an allogeneic fibroblast cell-based therapy designed to promote wound healing, particularly for difficult-to-treat diabetic foot ulcers.
CEO Pete O'Heeron stated that this engagement is important for establishing FibroBiologics' clinical trial infrastructure in Australia. The company, with 160+ patents issued and pending, focuses on developing therapeutics for chronic diseases using fibroblasts and fibroblast-derived materials.
FibroBiologics (Nasdaq: FBLG) has filed a patent application for generating three-dimensional hemopoietic organoids using fibroblast cell-based technology. This method could potentially produce therapeutic organoids capable of giving rise to various immune cells, including T cells, B cells, NK cells, and CAR-T cells. The process is described as rapid, cost-effective, and scalable, with organoids ready for transplantation within three days or cryopreserved for later use.
Dr. Hamid Khoja, Chief Scientific Officer, highlighted the potential for these organoids to be transplanted into living organisms to generate functional immune cells. CEO Pete O'Heeron emphasized that this patent, if issued, could allow FibroBiologics to develop a versatile solution for in vivo immune cell generation, potentially revolutionizing regenerative medicine and cancer immunotherapy.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, at the Lotte New York Palace Hotel. Pete O'Heeron, Founder and CEO, will represent the company.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company boasts over 160 issued and pending patents. Their presentation will be available on-demand to registered attendees starting September 9, 2024, at 7 a.m. Eastern Time.
Interested parties can find more information on FibroBiologics' website or by contacting info@fibrobiologics.com.
FibroBiologics (Nasdaq: FBLG) has filed a patent application for an adhesive bandage using fibroblast cell-based technology for wound healing. This innovative approach aims to leverage the healing properties of fibroblasts in a stable, room-temperature bandage suitable for post-surgical and retail use. The company, which focuses on developing therapeutics for chronic diseases using fibroblasts, sees this as an opportunity to expand its wound care platform and make advanced treatments more accessible.
CEO Pete O'Heeron highlighted the potential for a shelf-stable bandage, while CSO Hamid Khoja, Ph.D., emphasized the transformative potential of fibroblasts in wound care. With over 160 patents issued and pending, FibroBiologics continues to explore novel applications of fibroblast technology in healthcare.
FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company, has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, with the U.S. Securities and Exchange Commission. The company specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. FibroBiologics boasts a portfolio of over 150 issued and pending patents in this field. The quarterly report, which provides detailed financial and operational information for the second quarter of 2024, is now available for public viewing through a link on the company's investor relations website.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company, announced its participation in the JonesTrading Healthcare Seaside Summit on July 15, 2024, in San Diego. Founder and CEO Pete O'Heeron will present at 1:45 p.m. PDT. The presentation will be accessible via webcast, with replay links available on the company's Investor Relations page.
FibroBiologics specializes in developing therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials. The company holds over 150 patents issued and pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, wound healing, reversing organ involution, and cancer. Based in Houston, FibroBiologics represents the next generation of medical advancement in cell therapy.
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotech company, has developed a novel artificial thymus organoid capable of restoring immune function in severe combined immunodeficiency (SCID) mouse models. This organoid is made from fibroblasts and thymus-derived cells and can produce mature and diverse T cells, including CD4, CD8, and regulatory T cells. The company plans to develop this technology as a subcutaneous injection to restore thymus function lost due to aging or chemotherapy. Chief Scientific Officer Hamid Khoja emphasizes the potential of this technology in treating chronic inflammation and diseases linked to immune system dysregulation. CEO Pete O’Heeron believes the technology could revolutionize immunotherapy and serve as an alternative to stem cell transplantation.
FAQ
What is the current stock price of Fibrobiologics (FBLG)?
What is the market cap of Fibrobiologics (FBLG)?
